Author(s): Thaipisuttikul I, Chapman P, Avila EK, Thaipisuttikul I, Chapman P, Avila EK
Abstract Share this page
Abstract Ipilimumab, a monoclonal antibody targeting human cytotoxic T-lymphocyte-associated antigen 4, was approved by the FDA and European Medicines Agency for the treatment of metastatic melanoma. Immune-related adverse effects can occur with the use of this agent, but peripheral nervous system problems are rare. We report 2 cases of ipilimumab-induced polyneuropathy.
This article was published in J Immunother
and referenced in Immunome Research